Search

Search Constraints

You searched for: Author/Creator Misch, Martin

Search Results

1. ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS. (5th November 2018)

3. CTNI-07. LOMUSTINE/TEMOZOLOMIDE CHEMOTHERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED IDHWT GLIOBLASTOMA ACCORDING TO CETEG/NOA-09: REAL-WORLD EXPERIENCE IN A MULTICENTER COHORT. (14th November 2022)

5. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial. Issue 10172 (16th February 2019)

7. Robust methylation‐based classification of brain tumours using nanopore sequencing. Issue 1 (9th November 2022)

8. Loss of IDH mutation or secondary tumour manifestation? Evolution of an IDH‐mutant and 1p/19q‐codeleted oligodendroglioma after 15 years of continuous temozolomide treatment and radiotherapy: A case report. Issue 1 (14th December 2022)